Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | GLI1 | P08151 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760487 | 0.88 | BCHE (0.36) | DPP4GLI1BCHE | |
| SCHEMBL4760474 | 0.86 | GLI1 (0.35) | DPP4GLI1BCHE | |
| SCHEMBL1543311 | 0.86 | GLI1 (0.35) | DPP4GLI1BCHE | |
| SCHEMBL4103676 | 0.86 | GLI1 (0.35) | DPP4GLI1BCHE | |
| Hydrochloric Acid SCHEMBL2378323 | 0.86 | BCHE (0.36) | DPP4GLI1BCHE | |
| Hydrochloric Acid SCHEMBL13275366 | 0.84 | GLI1 (0.34) | DPP4GLI1BCHE | |
| Hydrochloric Acid SCHEMBL2804477 | 0.84 | GLI1 (0.34) | DPP4GLI1BCHE | |
| Hydrochloric Acid SCHEMBL17889948 | 0.84 | GLI1 (0.34) | DPP4GLI1BCHE | |
| SCHEMBL668995 | 0.84 | DPP4 (0.37) | DPP4GLI1BCHEALDH1A1TSHR | |
| SCHEMBL13275204 | 0.84 | DPP4 (0.37) | DPP4GLI1BCHEALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8039470-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039470-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | DPP4 2251/4885GLI1 1996/4885FASN 1384/4885 |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | DPP4 2251/4885GLI1 1996/4885FASN 1384/4885 |
| US-20100261665-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | DPP4 2251/4885GLI1 1996/4885FASN 1384/4885 |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | DPP4 2251/4885GLI1 1996/4885FASN 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.